{"id":"NCT05345691","sponsor":"Biocon Biologics UK Ltd","briefTitle":"Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis","officialTitle":"A Randomized, Double-Blind, Multicenter, Parallel-Arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-05-24","primaryCompletion":"2024-06-12","completion":"2024-06-12","firstPosted":"2022-04-26","resultsPosted":"2025-08-19","lastUpdate":"2025-09-09"},"enrollment":479,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Postmenopausal Women With Osteoporosis"],"interventions":[{"type":"BIOLOGICAL","name":"Bmab 1000","otherNames":[]},{"type":"BIOLOGICAL","name":"Prolia®","otherNames":[]}],"arms":[{"label":"Bmab 1000","type":"EXPERIMENTAL"},{"label":"Prolia®:","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, double-blind, multicenter, parallel-arm, Phase 3 study to compare the efficacy, PK (Pharmacokinetic), PD (Pharmacodynamic), safety, and immunogenicity of Bmab 1000 and Prolia® in postmenopausal women with osteoporosis","primaryOutcome":{"measure":"Percentage Change in Lumbar Spine BMD (Bone Mineral Density)","timeFrame":"Baseline and Week 52","effectByArm":[{"arm":"Bmab 1000 and Prolia","deltaMin":1.698,"sd":0.5115},{"arm":"Prolia®","deltaMin":1.44,"sd":0.5089}],"pValues":[]},"eligibility":{"minAge":"55 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":218},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","COVID-19","Urinary tract infection","Headache"]}}